MARKET

PLRX

PLRX

Pliant Therapeutics, Inc.
NASDAQ
12.73
-0.06
-0.47%
Pre Market: 13.00 +0.27 +2.12% 07:54 11/21 EST
OPEN
12.67
PREV CLOSE
12.79
HIGH
12.74
LOW
12.22
VOLUME
103
TURNOVER
0
52 WEEK HIGH
19.62
52 WEEK LOW
10.22
MARKET CAP
774.67M
P/E (TTM)
-3.8086
1D
5D
1M
3M
1Y
5Y
1D
Positive Developments in Pliant Therapeutics’ IPF Research Bolster Buy Rating
TipRanks · 2d ago
Pliant Therapeutics Reports Increased Losses and Strategic Focus
TipRanks · 2d ago
Pliant Therapeutics Presents Positive INTEGRIS-PSC Trial Data at The Liver Meeting® 2024
Barchart · 2d ago
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
Barchart · 2d ago
Weekly Report: what happened at PLRX last week (1111-1115)?
Weekly Report · 3d ago
Promising Pipeline and Strong Financials Reinforce Buy Rating for Pliant Therapeutics
TipRanks · 11/11 11:55
Weekly Report: what happened at PLRX last week (1104-1108)?
Weekly Report · 11/11 09:03
Buy Rating on Pliant Therapeutics Driven by Promising Bexotegrast Developments and Strategic Market Positioning
TipRanks · 11/11 06:26
More
About PLRX
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.

Webull offers Pliant Therapeutics Inc stock information, including NASDAQ: PLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLRX stock methods without spending real money on the virtual paper trading platform.